NCT04476862 - Cerliponase Alfa Observational Study in the US | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions

Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2

Interventions

DRUG

Cerliponase Alfa

Commercially available product provided to patient by participating clinic site.

DEVICE

Administration Kit

Commercially available administration kit provided to the patient by participating clinic site.

Trial Locations (16)

10017

NYU Langone Medical Center, New York

10029

Mt. Sinai School of Medicine, New York

14642

University of Rochester Medical Center, Rochester

20010

Children's National Hospital, Washington D.C.

30329

Children's Healthcare of Atlanta, Atlanta

32803

Advent Health, Orlando

43130

Nationwide Children's Hospital, Columbus

55404

Children's Hospital Minnesota, Minneapolis

60612

Rush University Medical Center, Chicago

72205

Arkansas Children's Hospital, Little Rock

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77030

Texas Children's Hospital, Houston

80045

Children's Hospital of Colorado, Aurora

92868

Children's Hospital of Orange County, Orange

02115

Boston Children's Hospital,, Boston

98145-5005

Seattle Children's Hospital, Seattle